header logo image


Page 113«..1020..112113114115..120..»

Archive for the ‘Stem Cell Therapy’ Category

International Stem Cell Corporation: A Company with Scores of Potential by Deborah Sterescu

Sunday, August 14th, 2011

International Stem Cell Corp (OTCBB:ISCO) is a company to watch this year, with several promising developments in store, according to a conference call with investors this morning.


The company, whose parthenogenetic stem cell technology can be used to derive pluripotent stem cells, meaning they can be transformed into any cell type in the body, has many important advantages at its fingertips.


Regenerative medicine is a market that is set to boom in the coming years, as more and more companies are developing therapies based on stem cell use. International Stem Cell's long-term goal is to be a universal supplier of stem cells for not just one, but a host of therapies.


The company's parthenogenetic stem cells are derived from unfertilized eggs, avoiding the ethical issues behind the destruction of viable human embryos, and giving cell-therapy companies one big reason to chose International Stem Cell as their supplier of choice when the time is right.
These parthenogenetic cells, like embryonic cells, also have the capacity to become almost any cell type in the body, but have demonstrated they are better in terms of the immune system, as one single stem cell line can be genetically matched to millions of people, reducing the need for immunosuppressants.


The company holds the world's largest collection of research-grade human parthenogenetic stem cell (hpSC) lines, which it uses along with its partners to investigate cellular therapies for a number of incurable human diseases.


Its plan is to establish a US bank of its clinical-grade human parthenogenetic stem cells that will be capable of being immune-matched to millions of patients, so that a physician could call up and request a specific cell type for people. The company, which recently received approvals to enroll around 3 US donors for its bank, already has a collection of ten human parthenogenetic stem cell lines used for research purposes, which were derived outside the US.


These cell lines could potentially be used to cure a number of diseases, including cancer, heart disease, liver disease, among many others. Already, the company has several trials in the works, and has successfully demonstrated in pre-clinical animal studies that its stem cells can be used to create viable liver cells.


Currently, efficacy tests in rat models are in progress for the liver cells, with results anticipated soon. If successful, the company said it plans on aggressively initiating the FDA process, with the aim of beginning first stage clinical trials sometime in 2012. The hope is that International Stem Cell will attain Fast Track designation, as few alternative options are available to patients suffering from liver disease.


The company also has trials in the works for Parkinson's disease and diseases of the eye, and is actively looking for collaborative or joint venture opportunities, as well as in-licensing and out-licensing arrangements.


In addition to its hugely potentially valuable stem cell therapy business, the company also two other operations that are set to generate revenue in the meantime. Lifeline Cell Technology, which saw sales grow by 35% in the first quarter, develops manufactures and markets the Lifeline brand of cell-culture products, which are used by researchers to grow human cells for pre-clinical research.


The subsidiary's products are developed using parent International Stem Cell's technology, and the company expects that as trials for researchers progress into more advanced stages, its technology will be embedded in this progress, potentially generating hundreds of millions of revenue.


In the last quarter, Lifeline Cell gained over 200 new customers due to new product introductions and the development of distribution channels internationally, a strategy it plans to continue.


Lastly, International Stem Cell's Lifeline Skin Care business sells skin care products based on its stem cells, having a very successful launch at the end of last year. The company planned on selling 1,000 products, but sold 7,000 initially, and plans to aggressively kick start major marketing initiatives again in September.


International Stem Cell is a company with scores of upside potential, and though future capital raising has not been ruled out, it has a facility that allows it to draw equity as necessary.
Register here to be notified of future International Stem Cell articles

Read More...

Part Two: The Ellis Martin Report – Interview with Ken Aldrich of International Stem Cell Corp.

Sunday, August 14th, 2011

International Stem Cell Corporation trades under the symbol ISCO.OB on the Over the Counter Bulletin Board and is based in Carlsbad, California where Ellis Martin had the pleasure of interviewing Executive Chairman Kenneth Aldrich. 


International Stem Cell has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISCO a unique leadership role in the field of regenerative cell therapy. Additionally, Lifeline Cell Technology, (a wholly-owned subsidiary of International Stem Cell Corporation (ISCO) develops, manufactures and markets high-quality human primary cells, stem cells, media and reagents for sale to pharmaceutical, academic and government scientists. 

The company's management pioneered the development of the normal human cell culture market through the creation of Clonetics® Corporation in the 1980s and has over 20 years combined experience in research, development, manufacturing, quality control, marketing and sales of human cell culture products. Lifeline's products are distributed in the United States and Europe. http://www.ellismartinreport.comhttp://www.intlstemcell.com contact: martinreports@gmail.com 
International Stem Cell is a paid sponsor of The Ellis Martin Report
Read More...

The Ellis Martin Report: Interview with Ken Aldrich of International Stem Cell Corp.

Sunday, August 14th, 2011

Your browser does not support the audio element.

Please click on the arrow above to listen to the complete interview.

"Ken Aldrich of International Stem Cell Corp (ISCO.OB) on the Present and Future of Stem Cell Research and Applications"

The Ellis Martin Report: International Stem Cell Corporation trades under the symbol ISCO.OB on the Over the Counter Bulletin Board and is based in Carlsbad, California where I have the pleasure of interviewing Executive Chairman, Kenneth Aldrich. International Stem Cell has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISCO a unique leadership role in the field of regenerative cell therapy. Additionally, Lifeline Cell Technology, a wholly-owned subsidiary of International Stem Cell Corporation (ISCO), develops, manufactures and markets high-quality human primary cells, stem cells, media and reagents for sale to pharmaceutical, academic and government scientists. The company’s management pioneered the development of the normal human cell culture market through the creation of Clonetics® Corporation in the 1980s and has over 20 years combined experience in research, development, manufacturing, quality control, marketing and sales of human cell culture products. Lifeline’s products are distributed in the United States and Europe. Ken Aldrich, welcome to the program.
For the complete text version of this broadcast: http://www.ellismartinreport.com/node/148

Read More...

Reminder: International Stem Cell Holding Business Update Conference Call on August 10

Sunday, August 14th, 2011

International Stem Cell Corporation (OTCBB:ISCO) reminds investors that it is holding a conference call and webcast on Wednesday, August 10, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). Chairman Ken Aldrich will provide an update on the business, including plans for the future development of the skin care line; animal and potential clinical trials for Parkinson's and liver diseases; and the Company's business strategy for 2011 and longer term.


Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers, or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company's Web site athttp://www.intlstemcell.com.


A telephone replay will be available approximately one hour after the conclusion of the call by dialing (877) 660-6853 for domestic callers, or 201-612-7415 for international callers, and entering the account code: 286 and the Conference ID: 376367. The webcast will be available on the Company's Web site for 60 days following the completion of the call.


About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.


To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

International Stem Cell Corporation

Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com

or:
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com

Read More...

Embryonic stem cell therapy in China (www.esctherapy.com)

Sunday, August 14th, 2011

Since 2002, ESC therapy has treated over 10000 patients with degenerative diseases, injury and cancer, now it has move on to help people to delay ageing as disease usually comes from weaken and aged cells.

View post:
Embryonic stem cell therapy in China (www.esctherapy.com)

Read More...

International Stem Cell Corporation Chairman Ken Aldrich Interviewed by Ellis Martin

Sunday, August 7th, 2011
"The Ellis Martin Report features interviews with exciting, potentially undervalued small and mid-cap publicly traded companies, showcased to an audience of potential retail investors during market hours throughout the United States."

Ellis Martin with Ken Aldrich of International Stem Cell Corporation (ISCO.OB)
Listen to full interview here: http://www.youtube.com/watch?v=WUyFYSGhNjc&feature=share or you can read a Transcript of the conversation here: http://www.ellismartinreport.com/node/148
(Scroll down to view this week's Radio Schedule for ISCO.)
“International Stem Cell Corporation trades under the symbol ISCO.OB on the Over the Counter Bulletin Board and is based in Carlsbad, California where Ellis Martin had the pleasure of interviewing Executive Chairman Kenneth Aldrich.
International Stem Cell has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISCO a unique leadership role in the field of regenerative cell therapy. Additionally, Lifeline Cell Technology, a wholly-owned subsidiary of International Stem Cell Corporation (ISCO) develops, manufactures and markets high-quality human primary cells, stem cells, media and reagents for sale to pharmaceutical, academic and government scientists.
The company's management pioneered the development of the normal human cell culture market through the creation of Clonetics® Corporation in the 1980s and has over 20 years combined experience in research, development, manufacturing, quality control, marketing and sales of human cell culture products. Lifeline Cell Tech’s products are distributed in the United States and Europe.”


Monday, August 1st at 1:00pm

WVNJ-NY/NJ - AM1160      

Tuesday, August 2nd at 10:00am
KCEO - AM1000    
San Diego/Orange County/LA Beach Cities

Tuesday, August 2nd at 9:30am and Friday, August 5th at 3:30pm
WSBR-AM - 740 FM 95.5  
Boca Raton, West Palm Beach, Ft. Lauderdale, Miami

Mondays and Wednesdays at 1:00pm
WBNM-AM 1120
Boston and New England through: WESO AM 970 and WCRN AM 830
Ellis Martin Report
http://www.ellismartinreport.com  
International Stem Cell Corporation
http://www.intlstemcell.com  
Contact: martinreports@gmail.com  
International Stem Cell Corporation is a paid sponsor of The Ellis Martin Report

Click here to listen to the entire interview: http://www.youtube.com/watch?v=WUyFYSGhNjc&feature=share

Read More...

International Stem Cell Corporation Chairman Ken Aldrich Interviewed by Ellis Martin

Sunday, August 7th, 2011
"The Ellis Martin Report features interviews with exciting, potentially undervalued small and mid-cap publicly traded companies, showcased to an audience of potential retail investors during market hours throughout the United States."

Ellis Martin with Ken Aldrich of International Stem Cell Corporation (ISCO.OB)
Listen to full interview here: http://www.youtube.com/watch?v=WUyFYSGhNjc&feature=share or you can read a Transcript of the conversation here: http://www.ellismartinreport.com/node/148
(Scroll down to view this week's Radio Schedule for ISCO.)
“International Stem Cell Corporation trades under the symbol ISCO.OB on the Over the Counter Bulletin Board and is based in Carlsbad, California where Ellis Martin had the pleasure of interviewing Executive Chairman Kenneth Aldrich.
International Stem Cell has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISCO a unique leadership role in the field of regenerative cell therapy. Additionally, Lifeline Cell Technology, a wholly-owned subsidiary of International Stem Cell Corporation (ISCO) develops, manufactures and markets high-quality human primary cells, stem cells, media and reagents for sale to pharmaceutical, academic and government scientists.
The company's management pioneered the development of the normal human cell culture market through the creation of Clonetics® Corporation in the 1980s and has over 20 years combined experience in research, development, manufacturing, quality control, marketing and sales of human cell culture products. Lifeline Cell Tech’s products are distributed in the United States and Europe.”


Monday, August 1st at 1:00pm

WVNJ-NY/NJ - AM1160      

Tuesday, August 2nd at 10:00am
KCEO - AM1000    
San Diego/Orange County/LA Beach Cities

Tuesday, August 2nd at 9:30am and Friday, August 5th at 3:30pm
WSBR-AM - 740 FM 95.5  
Boca Raton, West Palm Beach, Ft. Lauderdale, Miami

Mondays and Wednesdays at 1:00pm
WBNM-AM 1120
Boston and New England through: WESO AM 970 and WCRN AM 830
Ellis Martin Report
http://www.ellismartinreport.com  
International Stem Cell Corporation
http://www.intlstemcell.com  
Contact: martinreports@gmail.com  
International Stem Cell Corporation is a paid sponsor of The Ellis Martin Report

Click here to listen to the entire interview: http://www.youtube.com/watch?v=WUyFYSGhNjc&feature=share

Read More...

International Stem Cell Corporation to Hold Business Update Conference Call on August 10

Sunday, July 31st, 2011
International Stem Cell Corporation (OTCBB: ISCO) today announced that it will hold a conference call and webcast on Wednesday, August 10, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). Chairman Ken Aldrich will provide an update on the business, including plans for the future development of the skin care line; animal and potential clinical trials for Parkinson's and liver diseases; and the Company's business strategy for 2011 and longer term.
Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers, or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company's Web site athttp://www.intlstemcell.com.
A telephone replay will be available approximately one hour after the conclusion of the call by dialing 877-660-6853 for domestic callers, or 201-612-7415 for international callers, and entering the account code: 286 and the Conference ID: 376367. The webcast will be available on the Company's Web site for 60 days following the completion of the call.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com

or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com
Read More...

International Stem Cell Corporation to Hold Business Update Conference Call on August 10

Sunday, July 31st, 2011
International Stem Cell Corporation (OTCBB: ISCO) today announced that it will hold a conference call and webcast on Wednesday, August 10, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). Chairman Ken Aldrich will provide an update on the business, including plans for the future development of the skin care line; animal and potential clinical trials for Parkinson's and liver diseases; and the Company's business strategy for 2011 and longer term.
Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers, or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company's Web site athttp://www.intlstemcell.com.
A telephone replay will be available approximately one hour after the conclusion of the call by dialing 877-660-6853 for domestic callers, or 201-612-7415 for international callers, and entering the account code: 286 and the Conference ID: 376367. The webcast will be available on the Company's Web site for 60 days following the completion of the call.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com

or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com
Read More...

Stem Cell Therapy – Knee Surgery Alternative

Thursday, July 28th, 2011

Helen shares her experiences with Dr. Matos and the Jacksonville Anti-Aging Institute. Helen suffered from severe leg and knee pain, had problems walking, and was unable to bend her knees up to her chest.

Read more from the original source:
Stem Cell Therapy - Knee Surgery Alternative

Read More...

The New World of Medicine: Stem Cell Therapy

Tuesday, July 26th, 2011

In this video I will lay out my thinking as to why stem cell therapy is the next boom; it will in fact, change the world. What do you think?

Original post:
The New World of Medicine: Stem Cell Therapy

Read More...

Adult Stem Cell Therapy Clinical Advances – Dr. Jorge Paz in San Diego, CA March 2011

Tuesday, July 26th, 2011

Current treatments with Adipose-, Bone Marrow- and Cord Blood-derived stem cells. Autism, Multiple Sclerosis, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis and Osteoarthritis treatments are outlined. Dr.

Original post:
Adult Stem Cell Therapy Clinical Advances - Dr. Jorge Paz in San Diego, CA March 2011

Read More...

Regenerative Medicine With Stem Cell Therapy Injections at an Arizona pain clinic (602) 507-6550

Monday, July 25th, 2011

Amniotic Fluid Based Stem Cell Injections are being offered at Preferred Pain Center in Arizona. The injections offer an opportunity to harness the body's regenerative potential and exponentially increase it: 1) Anti-inflammation 2) Hyaluronic Acid 3) Stem Cells 4) Non-steroidal, non-embryonic treatment Pain relief plus potential regeneration of cartilage and soft tissues such as rotator cuff and ligaments. Now at Preferred Pain Center

Read the rest here:
Regenerative Medicine With Stem Cell Therapy Injections at an Arizona pain clinic (602) 507-6550

Read More...

The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper

Sunday, July 24th, 2011
International Stem Cell Corp (OTCBB: ISCO), a biotechnology company focused on therapeutic biomedical research and cosmeceutical products, operating in the same industry as companies like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC), aims to become the premier supplier of human cells and cell based products to the rapidly growing regenerative medicine industry.
International Stem Cell Corp (OTCBB: ISCO) specializes in manufacturing pluripotent human “partheno-genetic” stem cells that can be converted into any of the many specific types of cells that will be needed as regenerative medicine moves from the laboratory to the hospital or physician’s office.  ISCO’s cells have the same kind of ability to become any specific cell that might be needed for therapy as do the cells used by competitors like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC). Unlike the cells used by these competitors, however, ISCO’s cells are not obtained from fertilized embryos that might otherwise mature into a human child. Instead, they are derived from un-fertilized human eggs that would otherwise be destroyed and have no capacity to become a human child. Thus, ISCO’s parthenogenetic stem cells have removed a major ethical barrier to the use of the most prolific class of stem cells available to science today. With its patent on using the parthenogenesis process to make the stem cells, the company plans to establish partnerships, collaborations and licensing agreements with larger pharmaceutical companies to eventually unlock significant shareholder value.
Please read the complete article at The OTC Investor here
Read More...

International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

Sunday, July 24th, 2011
CARLSBAD, Calif. (July 20, 2011) – International Stem Cell Corporation (OTCBB: ISCO) announced today the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells.


The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSC), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).

ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, and thus have the capacity to become almost any cell type in the body. 

However, unlike hESCs, hpSCs can be created in a form such that cells from a single donor can be immunologically matched to millions of individuals.


Because no human embryos are ever damaged or destroyed in creating ISCO’s cells, they also avoid the ethical issues associated with embryonic hESC cells. ISCO maintains the world’s largest collection of research-grade hpSC lines.
Dr. Andrey Semechkin, the CEO of ISCO, comments: “The ability of neuronal cells to become a specific
type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.”
Parkinson’s disease is a disease of the central nervous system that affects millions of people worldwide.
PD patients present a range of possible symptoms, some of which are known to be as a result of the loss of dopaminergic neurons in the mid brain. ISCO’s approach is first to derive neuronal cells successfully from hpSC and, second, to evaluate their safety, functionality and efficacy using a series of in-house in vitro and in vivo models.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com .
To subscribe to receive ongoing corporate communications, please click on the following link: http://
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, the potential production and benefits of stem cell
lines, and other opportunities for the company and its subsidiaries, along with other statements about
the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, Ph.D.
Vice President
ras@intlstemcell.com
or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com
# # #

Read More...

The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper

Sunday, July 24th, 2011
International Stem Cell Corp (OTCBB: ISCO), a biotechnology company focused on therapeutic biomedical research and cosmeceutical products, operating in the same industry as companies like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC), aims to become the premier supplier of human cells and cell based products to the rapidly growing regenerative medicine industry.
International Stem Cell Corp (OTCBB: ISCO) specializes in manufacturing pluripotent human “partheno-genetic” stem cells that can be converted into any of the many specific types of cells that will be needed as regenerative medicine moves from the laboratory to the hospital or physician’s office.  ISCO’s cells have the same kind of ability to become any specific cell that might be needed for therapy as do the cells used by competitors like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC). Unlike the cells used by these competitors, however, ISCO’s cells are not obtained from fertilized embryos that might otherwise mature into a human child. Instead, they are derived from un-fertilized human eggs that would otherwise be destroyed and have no capacity to become a human child. Thus, ISCO’s parthenogenetic stem cells have removed a major ethical barrier to the use of the most prolific class of stem cells available to science today. With its patent on using the parthenogenesis process to make the stem cells, the company plans to establish partnerships, collaborations and licensing agreements with larger pharmaceutical companies to eventually unlock significant shareholder value.
Please read the complete article at The OTC Investor here
Read More...

International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

Sunday, July 24th, 2011
CARLSBAD, Calif. (July 20, 2011) – International Stem Cell Corporation (OTCBB: ISCO) announced today the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells.


The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSC), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).

ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, and thus have the capacity to become almost any cell type in the body. 

However, unlike hESCs, hpSCs can be created in a form such that cells from a single donor can be immunologically matched to millions of individuals.


Because no human embryos are ever damaged or destroyed in creating ISCO’s cells, they also avoid the ethical issues associated with embryonic hESC cells. ISCO maintains the world’s largest collection of research-grade hpSC lines.
Dr. Andrey Semechkin, the CEO of ISCO, comments: “The ability of neuronal cells to become a specific
type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.”
Parkinson’s disease is a disease of the central nervous system that affects millions of people worldwide.
PD patients present a range of possible symptoms, some of which are known to be as a result of the loss of dopaminergic neurons in the mid brain. ISCO’s approach is first to derive neuronal cells successfully from hpSC and, second, to evaluate their safety, functionality and efficacy using a series of in-house in vitro and in vivo models.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com .
To subscribe to receive ongoing corporate communications, please click on the following link: http://
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, the potential production and benefits of stem cell
lines, and other opportunities for the company and its subsidiaries, along with other statements about
the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, Ph.D.
Vice President
ras@intlstemcell.com
or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com
# # #

Read More...

Stem Cell Therapy–Hillcrest Animal Hospital

Tuesday, July 19th, 2011

Hillcrest Animal Hospital, Bartlett, TN.....now doing in house stem cell therapy to relieve clinical signs of arthritis in dogs To learn more about stem cell therapy and how its helping animals across the United States, visit http://www.medivet-america.com

Read more here:
Stem Cell Therapy--Hillcrest Animal Hospital

Read More...

International Stem Cell Corporation Congratulates Sweden’s Karolinska University Hospital on the Creation of the World’s First Artificial Trachea

Sunday, July 17th, 2011
International Stem Cell Corporation (ISCO) applauds the recent announcement by doctors at Sweden’s Karolinska University Hospital on the creation of the world’s first artificial trachea. 
ISCO would like our followers to understand that the concept of growing cells on a scaffold to treat diseases is showing success in our own research as exemplified by the following:
1) Collaboration with Cytograft in growing artificial blood vessels for treatment of lower limb ischemia. We are extremely proud and gratified to see how our FibroLife media manufactured by ISCO’s subsidiary Lifeline Cell Technology is effective in growing cells on threads used to “weave” artificial blood by Cytograft (as announced in ISCO’s recent press releases). 
2) The same technology is being used in ISCO’s work with Dr. Paul H. Chen wherein corneal epithelial cells are plated onto contact lenses (the “scaffold”) and used as a “living bandage” for laser eye surgery. 
International Stem Cell Corporation will continue to pursue the use of its cells and cell culture products in the many developing fields of regenerative medicine.
Read More...

International Stem Cell Corporation Congratulates Sweden’s Karolinska University Hospital on the Creation of the World’s First Artificial Trachea

Sunday, July 17th, 2011
International Stem Cell Corporation (ISCO) applauds the recent announcement by doctors at Sweden’s Karolinska University Hospital on the creation of the world’s first artificial trachea. 
ISCO would like our followers to understand that the concept of growing cells on a scaffold to treat diseases is showing success in our own research as exemplified by the following:
1) Collaboration with Cytograft in growing artificial blood vessels for treatment of lower limb ischemia. We are extremely proud and gratified to see how our FibroLife media manufactured by ISCO’s subsidiary Lifeline Cell Technology is effective in growing cells on threads used to “weave” artificial blood by Cytograft (as announced in ISCO’s recent press releases). 
2) The same technology is being used in ISCO’s work with Dr. Paul H. Chen wherein corneal epithelial cells are plated onto contact lenses (the “scaffold”) and used as a “living bandage” for laser eye surgery. 
International Stem Cell Corporation will continue to pursue the use of its cells and cell culture products in the many developing fields of regenerative medicine.
Read More...

Page 113«..1020..112113114115..120..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick